A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 299 participants.
Also called NCT01678820
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 299 participants
- Sponsor
- Registry
-
NCT01678820
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Terminated
Technical summary
Registry record NCT01678820. Randomized; double masking; primary purpose treatment. Start 2012-10-10 (actual); primary completion 2013-11-01 (actual). Results posted on 2014-10-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Sitagliptin/Simvastatin FDC
- Intervention (Drug)
- Sitagliptin
- Intervention (Drug)
- Simvastatin
- Intervention (Drug)
- Placebo to sitagliptin
- Intervention (Drug)
- Placebo to simvastatin
- Intervention (Drug)
- Placebo to Sitagliptin/Simvastatin FDC
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Glimepiride
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct01678820- Content hash
6c4c16b76107442b4a58f8d4dc5be122f1d2daf400efcd3c4eb8c7968de070df